The go-to stock for genomics just keeps going. It's likely that a fair number of the institutions that love Illumina (Nasdaq:ILMN) would stammer to explain exactly what their machines do, but they certainly know the stock is doing well.

TUTORIAL: Top Stock-Picking Strategies

Another Strong Quarter in the Books
Snarkiness aside, Illumina continues to deliver the sort of high-growth/low-competition story that growth investors dream about and so rarely find. Revenue rose another 47% this quarter, with sequencing sales leading the way at nearly 90% growth and sequencing consumables revenue growing about 70%. Arrays were weaker at 12% growth, but expectations were modest here anyway.

What may surprise some investors is how small Illumina still is. While this is clearly a legitimate growth stock star, the company booked about $283 million in revenue this quarter - on par with F5 (Nasdaq:FFIV) (another growth darling), but far smaller than software companies like VMware (NYSE:VMW) or (NYSE:CRM). Even within its own home market of life sciences, Illumina looks somewhat small when compared to names like Life Technologies (Nasdaq:LIFE), Waters (NYSE:WAT) or Thermo Fisher (NYSE:TMO). (For more, see A Fistful Of Life Sciences.)

In any case, profitability continues to improve, albeit not evenly. Gross margin actually fell about two points relatively to last year, but Illumina should be largely past its trade-in period, and ASPs for machines like the HiSeq should start to really improve. Operating income continues to grow nicely whether one uses the GAAP numbers (up 82%) or the non-GAAP (up 72%).

Illumina Is a Winner, But More Battles Loom
There is no question that Illumina is a force in sequencing and arrays. The question is whether the company can maintain that momentum. While the company has marginalized Affymetrix (Nasdaq:AFFX) in arrays, the acquisition of Ion Torrent has rejuvenated Life Technologies. This is particularly true in the "desktop" sequencing market - an emerging market that is still more theoretical than real, but nevertheless holds a lot of promise.

Longer term, there is even more competition on the horizon. Pacific Biosciences (Nasdaq:PACB) has built a lot of anticipation for its new products, while General Electric (NYSE:GE) and IBM (NYSE:IBM) continue to tease with what they may or may not have to offer the market in a few years. Keep in mind that each instrument sale can mean as much as $700,000 or more per year per instrument in consumables sales, so holding shares in instruments is critically important.

While there is talk of more spending on genomics in markets like pharmaceuticals, food safety and agriculture, it's been going on for quite a while now. The reality is that the biggest opportunities for companies like Illumina remain in academic labs and research hospitals where government funding is a major factor. The National Institute of Health's budget has not suffered as badly as some feared and genetic analysis is still a priority, but this could be a year-to-year risk for some time to come.

The Bottom Line
Illumina is past the point where reasonable discounted cash flow produces a viable fair valuation. So long as the growth continues, investors won't care. In the meantime, investors should also give some thought to names like Life Technologies, Waters and Thermo Fisher - none of these companies have the growth prospects of Illumina, but they have more diversified businesses and more reasonable valuations. By all means consider Illumina on the pullbacks, but keep in mind that the "easy" markets are more than half-penetrated and future growth may be more difficult or erratic than the optimists expect. (For more, see Time For A Diagnostics Test.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Time to Bring Active Back into a Portfolio?

    While stocks have rallied since the economic recovery in 2009, many active portfolio managers have struggled to deliver investor returns in excess.
  2. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  3. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  4. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  5. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  6. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  7. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  8. Investing

    What’s the Difference Between Duration & Maturity?

    We look at the meaning of two terms that often get confused, duration and maturity, to set the record straight.
  9. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  10. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center